Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$28.44 USD
+1.12 (4.10%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $28.36 -0.08 (-0.28%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RARE 28.44 +1.12(4.10%)
Will RARE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
Other News for RARE
Tactical Resources Announces Execution Of Amendment To Business Combination Agreement With Plum Acquisition Corp. III
Ultragenyx (RARE) Completes Enrollment for Phase 3 Study on Angelman Syndrome Treatment
Ultragenyx Pharmaceutical Inc (RARE) Advances Phase 3 Aspire Study for Angelman Syndrome ...
Ultragenyx completes enrollment of GTX-102 trial
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of ...